Regulatory compliance – Page 21

Vendor qualification failures during trial closeout – inspection observation risk

Management of Vendor Qualification Failures During Trial Closeout: An Actionable Playbook Vendor qualification failures during trial closeout pose significant risks to clinical trial integrity and regulatory compliance. Inadequate vendor assessments…

Safety reporting delays during regulatory inspection – regulatory expectations explained

Addressing Safety Reporting Delays in Regulatory Inspections: A Practical Playbook In the highly regulated pharmaceutical industry, safety reporting delays during regulatory inspections can lead to significant disruptions in product development…

Informed consent deficiencies during clinical trial conduct – preventing repeat GCP citations

Addressing Informed Consent Issues in Clinical Trials: A Practical Playbook Informed consent deficiencies during clinical trial conduct can lead to significant compliance challenges, including regulatory citations and jeopardized study integrity.…

Protocol deviation trends during database lock – inspection observation risk

Trends in Protocol Deviations During Database Lock: An Actionable Playbook Clinical trials are fundamental to drug development, but trends in protocol deviations during database lock can signal significant issues that…

Informed consent deficiencies during clinical trial conduct – TMF reconstruction strategy

Strategies for Managing Informed Consent Deficiencies in Clinical Trials Informed consent deficiencies during clinical trial conduct can pose significant risks to patient safety and regulatory compliance. These deficiencies not only…

Protocol deviation trends during clinical trial conduct – preventing repeat GCP citations

Strategies for Managing Protocol Deviation Trends in Clinical Trials Protocol deviations are common occurrences during the conduct of clinical trials, often leading to citations related to Good Clinical Practices (GCP)…

Protocol deviation trends during clinical trial conduct – regulatory expectations explained

Navigating Protocol Deviation Trends during Clinical Trial Conduct: A Playbook for Compliance In the dynamic landscape of clinical trials, protocol deviations are an inevitable challenge that can significantly impact study…

Informed consent deficiencies during sponsor audit – preventing repeat GCP citations

How to Address Informed Consent Deficiencies During Sponsor Audits and Prevent GCP Citations Informed consent is critical in clinical trials, ensuring that participants are fully aware of what they are…

Investigator oversight gaps during trial closeout – inspection observation risk

Addressing Investigator Oversight Gaps During Trial Closeout to Mitigate Inspection Risks Investigator oversight gaps during trial closeout can lead to significant risks in compliance, potentially inviting scrutiny from regulatory bodies…

Archival process non-compliant during routine studies – alignment with OECD principles

Managing Archival Process Non-Compliance During Routine Studies: A Practical Playbook In the pharmaceutical and laboratory setting, archival processes are essential for ensuring that study records are stored, retrievable, and compliant…

Deviation handling weak during routine studies – CAPA for GLP system gaps

Playbook for Strengthening Deviation Handling in Routine Studies Deviation handling is a critical aspect of pharmaceutical manufacturing and quality assurance. Weaknesses in this area can lead to compliance risks, impacting…

Archival process non-compliant during routine studies – preventing repeat GLP findings

Addressing Non-Compliant Archival Processes During Routine GLP Studies In the highly regulated pharmaceutical environment, compliance with Good Laboratory Practices (GLP) is critical. Non-compliance can lead to significant ramifications, including rejection…